Vanguard Group
ELTX icon

Vanguard Group’s Elicio Therapeutics ELTX Stock Holding History

Vanguard Group’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$3.96M Buy
496,901
+23,042
+5% +$209K ﹤0.01% 3344
2025
Q3 		$5.18M Buy
473,859
+19,240
+4% +$195K ﹤0.01% 3267
2025
Q2 		$3.51M Buy
454,619
+132,925
+41% +$827K ﹤0.01% 3324
2025
Q1 		$1.98M Buy
321,694
+75,871
+31% +$588K ﹤0.01% 3493
2024
Q4 		$1.2M Buy
245,823
+561
+0.2% +$2.76K ﹤0.01% 3703
2024
Q3 		$1.23M Buy
245,262
+18,965
+8% +$84K ﹤0.01% 3709
2024
Q2 		$930K Buy
226,297
+10,611
+5% +$89.7K ﹤0.01% 3809
2024
Q1 		$1.64M Buy
215,686
+40,792
+23% +$204K ﹤0.01% 3656
2023
Q4 		$1.46M Buy
174,894
+34,367
+24% +$224K ﹤0.01% 3712
2023
Q3 		$1.19M Buy
140,527
+69,777
+99% +$665K ﹤0.01% 3768
2023
Q2 		$672K Buy
70,750
+6,346
+10% +$58.2K ﹤0.01% 4029
2023
Q1 		$374K Hold
64,404
– – ﹤0.01% 4200
2022
Q4 		$523K Buy
64,404
+68
+0.1% +$618 ﹤0.01% 4085
2022
Q3 		$592K Sell
64,336
-12,733
-17% -$133K ﹤0.01% 4167
2022
Q2 		$878K Buy
77,069
+13,585
+21% +$217K ﹤0.01% 4129
2022
Q1 		$1.35M Sell
63,484
-26,829
-30% -$606K ﹤0.01% 4119
2021
Q4 		$2.62M Buy
90,313
+208
+0.2% +$10.5K ﹤0.01% 3941
2021
Q3 		$8.8M Buy
90,105
+64,876
+257% +$7.01M ﹤0.01% 3318
2021
Q2 		$3.29M Sell
25,229
-51,965
-67% -$7.5M ﹤0.01% 3802
2021
Q1 		$13.9M Buy
+77,194
New +$14.9M ﹤0.01% 2973

Other funds holding ELTX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Group's ELTX Position: Q4 2025 in Review

Vanguard Group increased its Elicio Therapeutics (ELTX) stake by 4.9% in Q4 2025, buying an estimated $209K and bringing the position to 496,901 shares worth $3.96M. The position accounts for ﹤0.01% of the portfolio, ranked #3344.

Vanguard Group first reported a position in ELTX in Q1 2021 and has held it in 20 quarters since. The position peaked at $13.9M in Q1 2021. 37 funds tracked by Wall St. Rank hold ELTX as of Q4 2025.

  • Vanguard Group held 496,901 shares of Elicio Therapeutics worth $3.96M as of Q4 2025.
  • Vanguard Group bought 23,042 Elicio Therapeutics shares in Q4 2025, an estimated $209K.
  • Elicio Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3344 holding.
  • Vanguard Group first reported a position in Elicio Therapeutics in Q1 2021 and has held it in 20 quarters since.
  • Vanguard Group's Elicio Therapeutics position peaked at $13.9M in Q1 2021.
  • 37 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.